For the Quarter Ending September 2025
North America
• In the USA, the Azithromycin Price Index rose by 0.57% quarter-over-quarter, reflecting restocking after destocking.
• The average Azithromycin price for the quarter was approximately USD 144060/MT, reported by surveyed participants.
• Azithromycin Spot Price volatility eased as logistics costs corrected and destocking pressures at distributors abated.
• Azithromycin Price Forecast signals modest upward drift as buyers restock ahead of anticipated year-end disruptions.
• Azithromycin Production Cost Trend remained stable as manufacturers absorbed moderate freight and input cost increases.
• Azithromycin Demand Outlook shows muted seasonal uptake with buyer caution and inventory normalization limiting procurement.
• Azithromycin Price Index remained rangebound while import surges and port delays produced regional price spikes.
• Inventories normalized across distributors, export demand softened, and major U.S. suppliers maintained stable operational utilization.
Why did the price of Azithromycin change in September 2025 in North America?
• Anticipatory stockpiling earlier in quarter reduced buying needs, sustaining downward pressure into September 2025 market.
• Logistics cost corrections and easing freight rates lowered landed costs, discouraging urgency for new purchases.
• Weaker consumer and business sentiment constrained downstream orders, prompting distributors to liquidate excess inventory instead.
APAC
• In China, the Azithromycin Price Index rose by 0.59% quarter-over-quarter in Q3 2025, reflecting recovery.
• The average Azithromycin price for the quarter was approximately USD 143916.67/MT, reported FOB Shanghai terms.
• Azithromycin Spot Price remained pressured by abundant export supply and subdued buying interest in June.
• Azithromycin Price Forecast shows modest recovery as restocking and improved demand slightly tighten export availability.
• Azithromycin Production Cost Trend eased as freight fell and input prices softened, relieving margin pressure.
• Azithromycin Demand Outlook remains cautious as western buyers delay purchases, maintaining subdued spot transaction volumes.
• Elevated inventories and weaker export demand pressured the Azithromycin Price Index, encouraging competitive seller offers.
• Some exporters curtailed output cycles during summer disruptions, tightening near-term availability and supporting price gains.
Why did the price of Azithromycin change in September 2025 in APAC?
• Supply overhang and accumulated inventories reduced seller pricing power, weakening export demand, pressuring spot markets.
• Falling freight and softer input prices reduced production costs, increasing buyer leverage and lowering offers.
• Cautious international procurement and tariff uncertainties delayed restocking, keeping demand outlook subdued and prices restrained.
Europe
• In Germany, the Azithromycin Price Index rose by 0.603% quarter-over-quarter, reflecting recovery from logistics disruptions.
• The average Azithromycin price for the quarter was approximately USD 144020.00/MT, confirmed by distributors nationwide.
• Tightened shipping windows elevated the Azithromycin Spot Price volatility, pressuring distributors to secure cargo quickly.
• Forward curves and clearance improvements shaped the Azithromycin Price Forecast suggesting gradual normalization over months.
• Stable raw material feedstocks kept the Azithromycin Production Cost Trend subdued, limiting pressure on margins.
• Domestic healthcare procurement and export demand supported the Azithromycin Demand Outlook, though buyers remained cautious.
• Elevated distributor stocks and deferred orders depressed volumes while the Azithromycin Price Index edged higher.
• Port congestion, Rhine barge constraints and seasonal restocking combined to tighten supply and raise bids.
Why did the price of Azithromycin change in September 2025 in Europe?
• Persistent port congestion and river transport constraints delayed shipments, reducing available immediate supply into German markets.
• Rising freight surcharges and rerouting increased landed costs and incentivized buyers to accelerate orders, pressuring spot availability.
• High distributor inventories earlier in quarter moderated price rises, but seasonal restocking reversed that trend during September.
For the Quarter Ending June 2025
North America
• The Azithromycin Dihydrate Price Index in the USA rose marginally by 0.34% in April 2025, driven by frontloading before the 145% U.S. tariff on Chinese goods and steady domestic demand.
• The Product Spot Price was influenced by increased landed costs and tighter supply chains as importers accelerated procurement ahead of the tariff deadline.
• May witnessed a sharp 4.40% drop in the Price Index amid declining imports from China, inventory rationalization, and a wait-and-watch approach following easing of U.S.–China tensions.
• A new executive order in mid-May introducing international benchmarking of drug prices reshaped buyer behavior, slowing purchases due to regulatory uncertainty.
• Product Production Cost Trend remained volatile as tariff-related cost recalibrations and logistics disruptions affected sourcing models across suppliers.
• In June, the Price Index declined slightly by 0.15% as market participants drew down inventory, and container rates from Asia corrected downward.
• Weakening domestic sentiment and ample stockpiles resulted in subdued Product Demand Outlook, especially from pharmacies and distributors.
• Suppliers postponed procurement amid inflation fears and mid-year financial pressures, impacting short-term pricing momentum.
• In July 2025, Product Spot Prices are likely to rise modestly due to localized supply tightness as suppliers cautiously manage restocking.
• Distributors are expected to scale back aggressive discounting, aiding in Product Price Forecast stabilization for early Q3 2025.
APAC
• April 2025 witnessed a marginal increase of +0.34% in the Price Index of Azithromycin Dihydrate FOB Shanghai, reaching a Product Spot Price of USD 147,500/MT, supported by domestic restocking and tight supply despite reduced U.S. demand.
• The Product Demand Outlook was stable domestically, driven by healthcare reforms and summer preparation, while international shipments pivoted to Europe and Asia amid U.S.-China trade tensions.
• Product Production Cost Trend remained under control due to sufficient inventories built in March, even though China’s PMI dipped to 49.0, reflecting a manufacturing slowdown.
• In May 2025, the Price Index fell sharply by -4.41%, with the Spot Price dropping to USD 141,000/MT, as export orders dried up and buyers paused due to tariff uncertainty.
• Manufacturing contraction and excessive inventory buildup due to overproduction in April added pressure, compelling suppliers to offer price discounts to clear stocks.
• Weak Product Demand Outlook in May was triggered by front-loaded April orders ahead of China’s Labor Day holidays, and muted recovery in export destinations despite tariffs lifting mid-month.
• June 2025 saw a further marginal decline of -0.21% in the Price Index, closing the month at USD 140,700/MT, amid growing overcapacity and subdued offtake.
• Falling global freight costs reduced the Product Production Cost Trend, which in turn weakened exporters' pricing power, encouraging more aggressive price competition.
• International buyers stayed inactive in June, citing adequate inventories and poor consumption trends, while domestic demand remained flat due to cautious procurement strategies.
• For July 2025, the Product Price Forecast signals a brief rebound as some overseas players are expected to resume buying to replenish inventory post-June lows; however, inventory pressure persists, likely moderating any steep gains.
Europe
• In April 2025, the Azithromycin Dihydrate Spot Price rose by 0.34% as the Price Index climbed due to seasonal logistics disruptions and rerouted global shipments, tightening supply in Germany.
• Calendar holidays such as Easter caused widespread delivery delays, while port congestion at Hamburg and other North European terminals further limited pharmaceutical inflow, influencing both supply and Product Price Forecast expectations.
• Buyers anticipated transit disruptions and engaged in proactive restocking, resulting in moderate demand strength and a firmer Product Demand Outlook, supported by improved consumer sentiment amid stable inflation (CPI at 2.1%).
• In May, the Price Index fell by -4.40% as downstream demand waned and stocks remained high due to diverted cargoes from China, originally meant for the U.S. but redirected after temporary American tariffs.
• Pharmaceutical procurement slowed as importers delayed fresh orders, reacting to heavy inventories and delayed post-holiday restocking, pushing suppliers to implement competitive pricing.
• Product Production Cost Trends remained steady, but downward pricing pressure was evident due to inventory surpluses and weakened demand, reinforcing a bearish outlook.
• In June, the Price Index decreased marginally (-0.19%) as quarter-end stock liquidation and delayed Peak Season Surcharges led to softer landed costs and encouraged cautious buying behavior.
• Despite continued port congestion, importers benefited from delayed surcharges, stabilizing landed prices and supporting a conservative procurement strategy for Azithromycin.
• The Product Demand Outlook in June remained muted, as buyers emphasized inventory optimization and risk mitigation, delaying fresh orders in a well-stocked market environment.
• For July 2025, the Azithromycin Dihydrate Price Index is likely to increase slightly, with downstream buyers expected to raise orders preemptively due to worsening port congestion and Rhine River barge delays, aiming to mitigate expected August disruptions.
For the Quarter Ending March 2025
North America
In Q1 2025, Azithromycin prices in the U.S. followed a volatile trajectory, influenced by shifting trade policies, supply chain challenges, and changing demand patterns. Prices rose moderately in January as importers accelerated purchases ahead of the proposed 10% tariff on Chinese goods set for February. This frontloading, combined with the approach of the Chinese Lunar New Year and rising energy costs, put additional strain on supply chains and pushed prices upward. Shipment delays intensified due to port congestion in Los Angeles, exacerbated by wildfire-related disruptions, further driving up operational expenses.
In February, prices declined as production in China recovered post-holiday and lower transpacific freight rates facilitated smoother supply into the U.S. Market demand softened due to economic uncertainty and earlier stockpiling, which dampened fresh purchasing activity. March saw a modest price rebound fueled by renewed buying interest after President Trump’s March 4 tariff measures targeting key trade partners stirred concerns over pharmaceutical supply continuity. Expectations of further tariffs in April prompted early procurement efforts, while slightly easing consumer inflation contributed to improved market sentiment and firmer pricing.
Overall, the first quarter showcased a turbulent yet resilient pricing landscape, underpinned by geopolitical developments and logistical pressures.
Asia Pacific
In the first quarter of 2025, Azithromycin prices in China experienced notable volatility, shaped by evolving supply-demand dynamics. In January, prices rose due to strong demand from the pharmaceutical and healthcare sectors, coupled with reduced manufacturing output during the Lunar New Year holiday. Exporters also frontloaded shipments ahead of anticipated U.S. tariffs, tightening domestic supply and driving bullish sentiment. February brought a slight price decline as post-holiday manufacturing recovery improved supply availability. However, demand remained subdued amid deflationary pressures, weak consumer spending, and a sluggish pharmaceutical market. The imposition of U.S. tariffs further contributed to higher domestic inventories, as exporters redirected volumes to local markets. By March, prices edged up again as supply struggled to keep pace with steady demand. Low stock levels, increased foreign procurement amid trade uncertainty, and stronger domestic demand—fueled by fiscal stimulus and restocking ahead of plant maintenance—tightened market conditions. Overall, the quarter saw a moderate price increase, driven by intermittent supply constraints and fluctuating demand.
Europe
In Q1 2025, Azithromycin prices in Germany experienced marked fluctuations, influenced by shifting demand, supply conditions, and external developments. January saw a moderate price increase, supported by improved business sentiment in Germany and accommodative monetary policy, which stimulated demand from the healthcare and pharmaceutical sectors. Stockpiling activity, prompted by anticipated delays linked to the Lunar New Year, added upward pressure on prices. In February, prices declined as supply remained ample and demand softened, reducing the urgency for new purchases. The strengthening Euro against the U.S. Dollar, combined with a steep drop in freight rates, made imports more cost-effective and contributed to an accumulation of inventories. By March, prices rebounded as supply constraints emerged due to port congestion and labor unrest across parts of Europe, which disrupted shipments. Restocking activities resumed, and growing confidence within the pharmaceutical sector lifted demand, driving a modest price recovery. Overall, Q1 ended with a moderate upward trend in Azithromycin prices, with market sentiment pointing to continued strength in the months ahead.
For the Quarter Ending December 2024
North America
In Q4 2024, Azithromycin prices in the USA experienced notable volatility, influenced by changing market conditions. October saw a slight uptick in prices, driven by increased demand following Federal Reserve rate cuts, which boosted consumer confidence. However, supply chain disruptions, including persistent port congestion, labor strikes, and concerns about potential tariff increases under President-elect Donald Trump, further strained the supply-demand balance, pushing prices higher.
In November, prices began to ease as demand softened, weighed down by inflationary pressures and elevated interest rates. A stronger U.S. dollar helped lower import costs, while the resolution of the ILA strike eased logistical bottlenecks. Coupled with well-stocked inventories, these factors allowed suppliers to reduce prices, offering relief to consumers.
By December, prices continued to drop due to diminishing consumer confidence, seasonal demand slowdowns, and proactive inventory building in anticipation of January strikes and the Chinese Lunar New Year. Inflationary concerns and uncertainty surrounding tariffs led to more cautious purchasing, while abundant supply and competitive pricing further pressured prices downward. Overall, Q4 2024 saw a fluctuating yet declining trend for Azithromycin prices.
Asia Pacific
In Q4 2024, the Azithromycin market in China displayed a fluctuating pricing pattern, shaped by changing economic conditions and market dynamics. October witnessed a significant price increase, driven by a resurgence in China’s manufacturing sector, bolstered by government stimulus efforts. With rising domestic and export demand, supported by monetary easing and a weaker yuan, consumer confidence surged, leading to higher external orders and enabling suppliers to raise prices.
However, by November, the upward trend reversed as high inventory levels, sluggish domestic demand, and weak international orders—particularly from the USA and Europe—created an oversupply. Falling crude oil prices further reduced production costs, prompting manufacturers to cut prices in order to remain competitive.
In December, prices continued to fall as consumer demand remained subdued amid ongoing disinflation in China. Changes in procurement strategies by pharmaceutical companies and international buyers contributed to weaker demand, while reduced foreign orders during the holiday season left suppliers with excess stock. This surplus prompted further price reductions as manufacturers sought to offload inventory before the year’s end. Overall, Q4 2024 saw a shift from early price increases to subsequent declines, driven by fluctuating demand and evolving market conditions.
Europe
In Q4 2024, Azithromycin prices in Germany followed a fluctuating trend throughout the quarter. October saw a modest price increase, fueled by a more optimistic business sentiment driven by hopes of economic recovery and the European Central Bank’s third interest rate cut to 3.25%. This monetary easing encouraged spending and investment, while supply chain disruptions at Hamburg’s ports and proactive inventory stockpiling added upward pressure on prices.
However, in November, the trend shifted as weaker demand from end-sectors and easing inflationary pressures led to price reductions. A notable drop in consumer spending and retail activity, along with a 1.9% decline in energy costs, lowered production expenses, allowing suppliers to reduce prices and stay competitive.
The downward trend persisted into December, driven by continued subdued demand from key sectors, cautious purchasing behavior amid ongoing inflation concerns, and higher import costs due to the euro’s depreciation. Elevated inventory levels and year-end clearance efforts further pushed prices lower, while harsh winter conditions disrupted logistics and dampened consumer activity. Overall, Q4 reflected a shift from early optimism to growing economic caution, leading to a volatile yet declining pricing environment.
